Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-16-010641
Filing Date
2016-02-05
Accepted
2016-02-05 16:47:09
Documents
59
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q1215_relmadatherap.htm 10-Q 392904
2 CERTIFICATION f10q1215ex31i_relmada.htm EX-31.1 18254
3 CERTIFICATION f10q1215ex31ii_relmada.htm EX-31.2 17362
4 CERTIFICATION f10q1215ex32i_relmada.htm EX-32.1 7096
5 CERTIFICATION f10q1215ex32ii_relmada.htm EX-32.2 7887
  Complete submission text file 0001213900-16-010641.txt   3128101

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE relm-20151231.xml EX-101.INS 582493
7 XBRL SCHEMA FILE relm-20151231.xsd EX-101.SCH 35448
8 XBRL CALCULATION FILE relm-20151231_cal.xml EX-101.CAL 31145
9 XBRL DEFINITION FILE relm-20151231_def.xml EX-101.DEF 144375
10 XBRL LABEL FILE relm-20151231_lab.xml EX-101.LAB 328234
11 XBRL PRESENTATION FILE relm-20151231_pre.xml EX-101.PRE 232761
Mailing Address 546 FIFTH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 FIFTH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-702-7163
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55347 | Film No.: 161392812
SIC: 2834 Pharmaceutical Preparations